Design of fluorine-containing 3,4-diarylfuran-2(5H)-ones as selective COX-1 inhibitors

ACS Medicinal Chemistry Letters

Volumn 5, Issue 11, 2014, Pages 1254-1258

  Uddin, Md Jashim ^a   Elleman, Anna V ^a   Ghebreselasie, Kebreab ^a   Daniel, Cristina K ^a   Crews, Brenda C ^a   Nance, Kellie D ^a   Huda, Tamanna ^a   Marnett, Lawrence J ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cyclooxygenase 1 (COX 1); furanone; imaging; rofecoxib; structure activity relationship

Indexed keywords

3,4 DIARYLFURAN 2(5H) ONE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ARACHIDONIC ACID; CARBON 14; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FK 881; FLUORINE; FLUORINE 18; FR 122047; FURANONE DERIVATIVE; MOFEZOLAC; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB; VU 0487836;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; OVARY CANCER; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84919883562     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500344j     Document Type: Article

References (30)

1. Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology Annu. Rev. Biochem. 2000, 69, 145-182
2. Vanhoutte, P. M. COX-1 and vascular disease Clin. Pharmacol. Ther. 2009, 86, 212-215
3. Choi, S. H.; Aid, S.; Bosetti, F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research Trends Pharmacol. Sci. 2009, 30, 174-181
4. Erovic, B. M.; Woegerbauer, M.; Pammer, J.; Selzer, E.; Grasl, M.; Thurnher, D. Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer Eur. J. Clin. Invest. 2008, 38, 61-66
5. Hwang, D.; Scollard, D.; Byrne, J.; Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer J. Natl. Cancer Inst. 1998, 90, 455-460
6. Kirschenbaum, A.; Klausner, A. P.; Lee, R.; Unger, P.; Yao, S.; Liu, X. H.; Levine, A. C. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate Urology 2000, 56, 671-676
7. Cho, M.; Kabir, S. M.; Dong, Y.; Lee, E.; Rice, V. M.; Khabele, D.; Son, D. S. Aspirin blocks EGF-stimulated cell viability in a COX-1 dependent manner in ovarian cancer cells J. Cancer 2013, 4, 671-678
8. Daikoku, T.; Tranguch, S.; Chakrabarty, A.; Wang, D.; Khabele, D.; Orsulic, S.; Morrow, J. D.; Dubois, R. N.; Dey, S. K. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer Cancer Res. 2007, 67, 5285-5292
9. Dore, M.; Cote, L. C.; Mitchell, A.; Sirois, J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas J. Histochem. Cytochem. 1998, 46, 77-84
10. Gupta, R. A.; Tejada, L. V.; Tong, B. J.; Das, S. K.; Morrow, J. D.; Dey, S. K.; DuBois, R. N. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer Cancer Res. 2003, 63, 906-911
11. Lee, C. Y.; Chen, K. W.; Sheu, F. S.; Tsang, A.; Chao, K. C.; Ng, H. T. Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody Cancer Immunol. Immunother. 1992, 35, 19-26
12. Cekanova, M.; Uddin, M. J.; Bartges, J. W.; Callens, A.; Legendre, A. M.; Rathore, K.; Wright, L.; Carter, A.; Marnett, L. J. Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo Cancer Prev. Res. 2013, 6, 466-476
13. Uddin, M. J.; Crews, B. C.; Blobaum, A. L.; Kingsley, P. J.; Gorden, D. L.; McIntyre, J. O.; Matrisian, L. M.; Subbaramaiah, K.; Dannenberg, A. J.; Piston, D. W.; Marnett, L. J. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents Cancer Res. 2010, 70, 3618-3627
14. Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Huda, I.; Kingsley, P. J.; Ansari, M. S.; Tantawy, M. N.; Reese, J.; Marnett, L. J. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer Cancer Prev. Res. 2011, 4, 1536-1545
15. Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Marnett, L. J. Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents Bioconjugate Chem. 2013, 24, 712-723
16. Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Tantawy, M. N.; Marnett, L. J. [I]-Celecoxib analogues as SPECT tracers of cyclooxygenase-2 in inflammation ACS Med. Chem. Lett. 2011, 2, 160-164
17. Perrone, M. G.; Malerba, P.; Uddin, M. J.; Vitale, P.; Panella, A.; Crews, B. C.; Daniel, C. K.; Ghebreselasie, K.; Nickels, M.; Tantawy, M. N.; Manning, H. C.; Marnett, L. J.; Scilimati, A. PET radiotracer [(1)(8)F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation Eur. J. Med. Chem. 2014, 80, 562-568
18. Teng, X. W.; Abu-Mellal, A. K.; Davies, N. M. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat J. Pharm. Pharm. Sci. 2003, 6, 205-210
19. Fukai, R.; Zheng, X.; Motoshima, K.; Tai, A.; Yazama, F.; Kakuta, H. Design and synthesis of novel cyclooxygenase-1 inhibitors as analgesics: 5-amino-2-ethoxy- N -(substituted-phenyl)benzamides ChemMedChem 2011, 6, 550-560
20. Kakuta, H.; Zheng, X.; Oda, H.; Harada, S.; Sugimoto, Y.; Sasaki, K.; Tai, A. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor J. Med. Chem. 2008, 51, 2400-2411
21. Liedtke, A. J.; Crews, B. C.; Daniel, C. M.; Blobaum, A. L.; Kingsley, P. J.; Ghebreselasie, K.; Marnett, L. J. Cyclooxygenase-1-selective inhibitors based on the (E)-2′-des-methyl-sulindac sulfide scaffold J. Med. Chem. 2012, 55, 2287-2300
22. Calvello, R.; Panaro, M. A.; Carbone, M. L.; Cianciulli, A.; Perrone, M. G.; Vitale, P.; Malerba, P.; Scilimati, A. Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells Pharmacol. Res. 2012, 65, 137-148
23. Di Nunno, L.; Vitale, P.; Scilimati, A.; Tacconelli, S.; Patrignani, P. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal J. Med. Chem. 2004, 47, 4881-4890
24. Imanishi, J.; Morita, Y.; Yoshimi, E.; Kuroda, K.; Masunaga, T.; Yamagami, K.; Kuno, M.; Hamachi, E.; Aoki, S.; Takahashi, F.; Nakamura, K.; Miyata, S.; Ohkubo, Y.; Mutoh, S. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor Biochem. Pharmacol. 2011, 82, 746-754
25. Kusuhara, H.; Fukunari, A.; Matsuyuki, H.; Okumoto, T. Principal involvement of cyclooxygenase-1-derived prostaglandins in the c-fos expression of the rat hind brain following visceral stimulation with acetic acid Brain Res. Mol. Brain Res. 1997, 52, 151-156
26. Ochi, T.; Motoyama, Y.; Goto, T. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models Eur. J. Pharmacol. 2000, 391, 49-54
27. Ono, N.; Yamamoto, N.; Sunami, A.; Yamasaki, Y.; Miyake, H. Pharmacological profile of mofezolac, a new non-steroidal analgesic anti-inflammatory drug Nihon Yakurigaku Zasshi 1990, 95, 63-81
28. Smith, C. J.; Zhang, Y.; Koboldt, C. M.; Muhammad, J.; Zweifel, B. S.; Shaffer, A.; Talley, J. J.; Masferrer, J. L.; Seibert, K.; Isakson, P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13313-13318
29. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H -pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) J. Med. Chem. 1997, 40, 1347-1365
30. Yamakawa, N.; Suzuki, K.; Yamashita, Y.; Katsu, T.; Hanaya, K.; Shoji, M.; Sugai, T.; Mizushima, T. Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity Bioorg. Med. Chem. 2014, 22, 2529-2534